Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer
Leora Horn(Vanderbilt University), Christine M. Lovly(Dana-Farber Cancer Institute), Liping Du(Vanderbilt University Medical Center), Allison Holzhausen(Xcovery (United States)), Mark Li(University of Iowa), Heather A. Wakelee(Palo Alto Institute), Geoffrey R. Oxnard(Foundation Medicine (United States)), Vincent Huang(Vanderbilt University Medical Center), Kavita Garg, Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Lee P. Lim, Sandip Pravin Patel(University of California San Diego), Tristan Shaffer, Jorge J. Nieva(University of Southern California), Jennifer G. Whisenant(Vanderbilt-Ingram Cancer Center), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Saiama N. Waqar(Washington University in St. Louis), Huan Qiao(Vanderbilt University Medical Center), Jennifer Hernandez, Kimberly Harrow(Xcovery (United States)), Rachel E. Sanborn(Providence Portland Medical Center), Chris Liang(Xcovery (United States)), Ticiana Leal(University of Wisconsin Carbone Cancer Center)
Cited by 163
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k